EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inflammation and Cardiovascular Disease – a narrative review

Peter Poredos, Pavel Poredos

Slovenian Medical Journal · 30.04.2026 · 1-12

DOI: 10.6016/zdravvestn.3687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Slovenian Medical Journal, online erschienen am 30.04.2026. Verfasst von Peter Poredos und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic inflammation is a key mechanism in atherosclerosis and is associated with different stages of the atherosclerotic process and its complications. Cytokines, including interleukins, amplify the inflammatory cascade within the vessel wall and play a critical role throughout the pathogenetic process of atherosclerosis. Most risk factors for atherosclerosis exert harmful effects on the vessel wall by inducing an inflammatory process. Several inflammatory biomarkers are available to identify low-grade inflammation. Incorporating determination of inflammatory biomarkers, especially highly sensitive CRP (hsCRP), into CV risk prediction in primary prevention may help reclassify CV risk, particularly in low-risk patients and in subjects in whom traditional risk scores do not provide an exact estimation of risk. However, the existing guidelines do not include any inflammatory biomarkers in their scoring systems. A healthy lifestyle, including exercise, weight loss, and smoking cessation, has been shown to reduce CV events by reducingng systemic inflammatory response. Also, drug treatment of risk factors, including antihypertensive agents and lipid-lowering drugs, reduces levels of circulating inflammatory biomarkers. With statins, it has been shown that the greatest reduction in ischemic events was achieved in patients with reduced low-density lipoprotein cholesterol and hsCRP. Despite the effects on levels of inflammatory biomarkers, only a limited number of anti-inflammatory agents have shown convincing results in lowering CV risk. Targeting interleukins, particularly interleukin-6, represents the most compelling evidence for reducing CV events. Canakinumab, colchicines, and some other new anti-inflammatory drugs are promising. However, further studies will be needed to determine the specific inflammatory mechanisms that contribute to CV events and to identify novel therapeutic strategies.

Zitieren

APA

Poredos, P., & Poredos, P. (2026). Inflammation and Cardiovascular Disease – a narrative review. Slovenian Medical Journal, 1-12. https://doi.org/10.6016/zdravvestn.3687

Vancouver

Poredos P, Poredos P. Inflammation and Cardiovascular Disease – a narrative review. Slovenian Medical Journal. 2026:1-12. doi:10.6016/zdravvestn.3687

BibTeX
@article{Poredos2026,
  author = {Poredos, Peter and Poredos, Pavel},
  title = {Inflammation and Cardiovascular Disease – a narrative review},
  journal = {Slovenian Medical Journal},
  year = {2026},
  pages = {1--12},
  doi = {10.6016/zdravvestn.3687}
}
Kostenlos starten →